Onco Actu du 18 mai 2020

	3.6 PRÉVENTION - ACTIVITÉ PHYSIQUE
For Women with Breast Cancer, Regular Exercise May Improve Survival [NCI] The study was unusual in that it collected information on the physical activity levels of women with high-risk breast cancer (cancer that is likely to recur or spread) at multiple time points—shortly before their diagnosis, during chemotherapy, and after completion of treatment.
	4.2 DÉP., DIAG. & PRONO. - GÉNOME
Genome-wide pattern found in tumors from brain cancer patients predicts life expectancy [University of Utah] The team uncovered the relationship by developing and using new mathematical methods to compare and contrast tumor and normal whole genomes from the Cancer Genome Atlas (TCGA), a publicly open national database.
	5.12.10 IMMUNOTHÉRAPIES - FUSIONS ET ACQUISITIONS
Looking for first-in-class glory, Boehringer Ingelheim acquires two preclinical cancer drugs from Versant-backed biotech [EndPoints] What unites the two acquired programs, according to Jonathon Sedgwick, Boehringer’s global head of cancer immunology and immune modulation research, is that they target “cold” tumors.
	5.12.6 IMMUNOTHÉRAPIES - AMM
Bristol Myers Squibb finally breaks into first-line lung cancer with Opdivo-Yervoy nod [Fierce Pharma] Of course, racking up revenue in the new indication won’t be easy, considering Bristol’s duo will have to go up against Merck & Co.’s formidable Keytruda-chemo combo, which has shown it can slash patients’ risk of death by 51%—no matter their PD-L1 status.
U.S. Food and Drug Administration Approves Opdivo® (nivolumab) + Yervoy® (ipilimumab) as First-Line Treatment of Patients with Metastatic Non-Small Cell Lung Cancer Whose Tumors Express PD-L1≥1% [BMS] Fifth indication for Opdivo + Yervoy, the first and only FDA-approved dual immunotherapy.
FDA approves nivolumab plus ipilimumab for first-line mNSCLC (PD-L1 tumor expression ≥1%) [FDA] Efficacy was investigated in CHECKMATE-227 (NCT02477826), a randomized, open-label, multi-part trial in patients with metastatic or recurrent NSCLC and no prior anticancer therapy.
	5.2 PHARMA
Enhertu granted Breakthrough Therapy Designation in the US for HER2-mutant metastatic non-small cell lung cancer [AstraZeneca] Third Breakthrough Therapy Designation for Enhertu (trastuzumab deruxtecan).
	5.2.3 PHARMA - ÉCONOMIE
ADC’s $233M IPO Brings It to NYSE With Cancer Drug Launch on Horizon [Xconomy] The company’s lead drug, loncastuximab tesirine, or “Lonca,” is in a pivotal Phase 2 test evaluating it as a treatment for diffuse large B-cell lymphoma (DLBCL).
	5.2.6 PHARMA - BIOTECH
Blueprint's Ayvakit gets FDA no-go in new stomach cancer use but presses ahead in blood disorder [Fierce Pharma] Besides Ayvakit, Blueprint is awaiting an FDA decision for its RET inhibitor pralsetinib—a potential rival to Eli Lilly’s newly approved Retevmo—in RET-driven non-small cell lung cancer.
After a PhIII failure, the FDA delivers Blueprint an expected CRL [EndPoints] The best promise for GIST patients without the PDFRa mutation now lies with Deciphera, which has been going to head to head with Blueprint on the indication for a year. The company’s drug, ripretinib, has earned a breakthrough designation and a priority review for fourth-line GIST, setting up a decision in August.
	5.3.4.1 TRAITEMENTS - AMM (FDA, EMA,...) - RUCAPARIB
Rubraca® (Rucaparib) Approved In The U.S. As Monotherapy Treatment For Patients With BRCA1/2-Mutant, Metastatic Castration-Resistant Prostate Cancer (MCRPC) Who Have Been Treated With Androgen Receptor-Directed Therapy And A Taxane-Based Chemotherapy [Clovis Oncology] Rubraca is the first PARP inhibitor approved in a prostate cancer setting.
FDA grants accelerated approval to rucaparib for BRCA-mutated metastatic castration-resistant prostate cancer [FDA] Efficacy was investigated in TRITON2 (NCT02952534), an ongoing, multi-center, single arm clinical trial in 115 patients with BRCA-mutated (germline and/or somatic) mCRPC who had been treated with androgen receptor-directed therapy and taxane-based chemotherapy.
	5.3.4.2 TRAITEMENTS - AMM (FDA, EMA,...) - RIPRETINIB
Deciphera Pharmaceuticals Wins Early FDA Nod for GI Cancer Treatment [Xconomy] The company submitted ripretinib for regulatory review after the drug hit its main goal in a Phase 3 trial, INVICTUS, which enrolled 129 patients with gastrointestinal stromal tumors (GIST) who have failed at least three treatments.
FDA Grants Full Approval of Deciphera Pharmaceuticals’ QINLOCK™ (ripretinib) for the Treatment of Fourth-Line Gastrointestinal Stromal Tumor [Deciphera] QINLOCK Significantly Improved Progression-Free Survival and Showed Clinically Meaningful Overall Survival in INVICTUS Phase 3 Study.
FDA Approves First Drug for Fourth-Line Treatment of Advanced Gastrointestinal Stromal Tumors [FDA] The U.S. Food and Drug Administration approved Qinlock (ripretinib) tablets as the first new drug specifically approved as a fourth-line treatment for advanced gastrointestinal stromal tumor (GIST), a type of tumor that originates in the gastrointestinal tract.
	5.5.1.1 ASCO (GÉNÉRAL) - INDUSTRIELS
Novartis data at ASCO and EHA showcase bold approaches to reimagine cancer and blood disorders through multiple therapeutic platforms [Novartis] New Kisqali® (ribociclib)* overall survival subgroup analysis in HR+/HER2- advanced breast cancer (ABC) and additional Piqray® (alpelisib) data in patients in HR+/HER2- ABC patients with a PIK3CA mutation.
	5.5.15 ASCO (BIOPSIES LIQUIDES)
Guardant Health Data at ASCO and AACR Demonstrates Growing Value of Liquid Biopsy for Precision Oncology in Advanced and Early Stage Cancer [Guardant Health] Key findings demonstrate high concordance with tissue biopsies, the advantages over tissue biopsies to detect clinically relevant mutations for rule-in and rule-out decisions, and feasibility of serial testing from patient plasma to reveal tumor evolution and resistance in response to intervening therapies, including immunotherapies.
	5.9.3 EHA
AbbVie Data at EHA Annual Congress Highlight Depth and Breadth of Transformative Blood Cancer Portfolio [AbbVie] Presentations of data from the CLL14 trial evaluating venetoclax in combination with obinutuzumab in patients with previously-untreated CLL (abstract #S155).
	6.1 OBSERVATION
Geography of childhood cancer in Switzerland studied [University of Bern] The group found evidence of increased risks in certain areas, particularly for brain tumors. The researchers demand that the search for the causes of brain tumors in children be intensified.
	6.15 LUTTE CONTRE LES CANCERS - COVID-19
Protecting “covid-protected” cancer hubs [BMJ] For truly “covid-protected” cancer treatment, it will therefore be essential to regularly screen asymptomatic staff in cancer hubs who interact with patients, and who may be carriers of covid-19.
Treatment Guidance for Lung Cancer Patients During the COVID-19 Pandemic - Journal of Thoracic Oncology Publishes Comprehensive Overview [IASLC] “The purpose of this manuscript is to present a practical multidisciplinary and international overview to assist in treatment for lung cancer patients during this pandemic, with the caveat that evidence is lacking in many areas.”